All In Biotech

Free tool

FAERS Monitor: Imdelltra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761344 or its brand name (Imdelltra, Tarlatamab-Dlle). Reports on generic versions are filed under their own applications.

Reports

10

Serious

10

100% of reports

Hospitalization

5

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cytokine release syndrome4
  • immune effector cell-associated neurotoxicity syndrome4
  • acute respiratory failure2
  • dyspnoea2
  • fatigue2
  • pain2
  • adverse event1
  • asthenia1
  • atrial fibrillation1
  • cardio-respiratory arrest1
  • cardiomyopathy1
  • cardiovascular disorder1
  • chest pain1
  • chills1
  • decreased appetite1

Reports by year received

View as table
YearReports
20243
20253
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
immune effector cell-associated neurotoxicity syndromeSignal41421.4665.04,344
cytokine release syndromeSignal4419.5196.31,279
acute respiratory failure2218.763.3243
cardiomyopathy1142.322.235
cardiovascular disorder182.812.920
cardio-respiratory arrest150.37.812
adverse event122.83.65
atrial fibrillation121.63.44
chills117.92.84
chest pain111.41.82
decreased appetite19.11.41
dyspnoea27.42.26
pain26.82.05
asthenia15.60.91
fatigue25.41.64

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.